EDNRB and cancer: Beyond fibrosis, EDNRB dysregulation influences cancer progression: low EDNRB expression promotes metastasis via ERK pathway activation, whereas bosentan suppresses tumor cell migration by 62% and reverses epithelial-mesenchymal transition (38).